{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:12:41Z","timestamp":1776741161159,"version":"3.51.2"},"reference-count":29,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Regional Development Fund","award":["01-1-23 2"],"award-info":[{"award-number":["01-1-23 2"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background\/Objectives: Most patients with non-small cell lung cancer (NSCLC) receive chemo- and\/or immunotherapy, which can be associated with adverse events including fatigue. Affected patients may not be able to receive the complete chemo- and\/or immunotherapy as planned. In this context, patients may benefit from maintaining their physical activity, which can be challenging. An app reminding patients to perform a certain number of steps may have a positive effect on physical activity during chemo- and\/or immunotherapy. Such an app is under development and will be tested in a prospective trial. The current APACHIE-01 study (NCT06993896) is required for proper sample size calculation and design of the planned trial. Methods: The main goal of the APACHIE-01 study is to evaluate patterns and predictors of physical activity during chemo- and\/or immunotherapy for locally advanced or metastatic NSCLC. The primary endpoint is the assessment of the mean number of steps per week during the first three cycles of chemo- and\/or immunotherapy for lung cancer. The baseline value is represented by the mean number of steps during the last week prior to chemotherapy and\/or immunotherapy. Secondary endpoints include associations between mean number of steps per week and a pain score, a distress score, and a fatigue score. The recruitment of the required 38 patients should be completed within 4 months and the treatment period will be 9\u201310 weeks (three cycles of chemo- and\/or immunotherapy), resulting in a total running time of approximately 6 months. The APACHIE-01 study will contribute to the optimal design of a subsequent prospective trial.<\/jats:p>","DOI":"10.3390\/clinpract15080139","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T16:06:17Z","timestamp":1753459577000},"page":"139","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Physical Activity During Chemotherapy and\/or Immunotherapy for Non-Small Cell Lung Cancer (NSCLC): Protocol of the APACHIE-01 Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Dirk","family":"Rades","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"},{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, L\u00fcbeck Campus, 23538 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Doehring","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, L\u00fcbeck Campus, 23538 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Staackmann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, L\u00fcbeck Campus, 23538 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Karolin","family":"Streubel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University Medical Center Schleswig-Holstein, L\u00fcbeck Campus, 23538 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of L\u00fcbeck, 23562 L\u00fcbeck, Germany"},{"name":"Medical Practice for Radiotherapy and Radiation Oncology, 30161 Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6149-465X","authenticated-orcid":false,"given":"Tobias","family":"Bartscht","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Stem Cell Transplantation, Helios Hospital Schwerin, 19055 Schwerin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Bohnet","sequence":"additional","affiliation":[{"name":"Department of Pulmonology, University Medical Center Schleswig-Holstein, L\u00fcbeck Campus, 23538 L\u00fcbeck, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2025, May 16). Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Langversion 3.0, 2024, AWMF-Registernummer: 020-007OL. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/lungenkarzinom\/."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gong, S., Li, Q., Yu, X., and Yang, S. (2024). Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: A network meta-analysis. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1362537"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102751","DOI":"10.1016\/j.ctrv.2024.102751","article-title":"Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations","volume":"127","author":"Rached","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.annonc.2019.10.003","article-title":"Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer","volume":"31","author":"Nackaerts","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sforza, V., Palumbo, G., Cascetta, P., Carillio, G., Manzo, A., Montanino, A., Sandomenico, C., Costanzo, R., Esposito, G., and Laudato, F. (2022). BRAF inhibitors in non-small cell lung cancer. Cancers, 14.","DOI":"10.3390\/cancers14194863"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jcpt.13534","article-title":"The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab\/pemetrexed alone for stage IIIB\/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials","volume":"47","author":"Liu","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mei, T., Wang, T., Deng, Q., and Gong, Y. (2023). The safety of combining immune checkpoint inhibitors and platinum-based chemotherapy for the treatment of solid tumors: A systematic review and network meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1062679"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bai, L., Ni, L., Lu, J., Zhang, Y.Y., Yin, Y., Zhang, W., and Duan, X. (2024). Relationship between nausea and vomiting and physical activity in patients with lung cancer undergoing first chemotherapy. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1396637"},{"key":"ref_11","first-page":"3169","article-title":"Effects of exercise training on exercise capacity in patients with non-small cell lung cancer receiving targeted therapy","volume":"20","author":"Hwang","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1249\/MSS.0000000000000158","article-title":"Exercise in patients with non-small cell lung cancer","volume":"46","author":"Kuehr","year":"2014","journal-title":"Med. Sci. Sports Exerc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15347354231168368","DOI":"10.1177\/15347354231168368","article-title":"Dose delays, dose reductions, and relative total dose intensity in patients with advanced cancer who exercised during neoadjuvant chemotherapy treatment","volume":"22","author":"Wonders","year":"2023","journal-title":"Integr. Cancer Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/1534735415572887","article-title":"The impact of a multidimensional exercise intervention on physical and functional capacity, anxiety, and depression in patients with advanced-stage lung cancer undergoing chemotherapy","volume":"14","author":"Quist","year":"2015","journal-title":"Integr. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2020.05.003","article-title":"Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial","volume":"145","author":"Quist","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_16","first-page":"95","article-title":"Strength and endurance training in the treatment of lung cancer patients in stages IIIA\/IIIB\/IV","volume":"22","author":"Henke","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_17","first-page":"2863","article-title":"Physiologic and psychologic adaptation to exercise interventions in lung cancer patients undergoing chemotherapy: A systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Lee","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2147\/JMDH.S311225","article-title":"Impact of physical inactivity on the risk of disability and hospitalization in older patients with advanced lung cancer","volume":"14","author":"Yonenaga","year":"2021","journal-title":"J. Multidiscip. Healthc."},{"key":"ref_19","first-page":"845","article-title":"The association between physical activity levels and quality of life in elderly lung cancer patients undergoing chemotherapy in China: A cross-sectional study","volume":"32","author":"Hou","year":"2024","journal-title":"Support. Care Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/1759-7714.15272","article-title":"Safety and efficacy evaluation of personalized exercise prescription during chemotherapy for lung cancer patients","volume":"15","author":"Li","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fukushima, T., Katsushima, U., Ogushi, N., Hase, K., and Nakano, J. (2024). Physical activity and prognosis and factors associated with low physical activity in patients with advanced or recurrent lung cancer: A retrospective, observational study. BMJ Support. Palliat. Care, spcare-2024-005122. (online ahead of print).","DOI":"10.1136\/spcare-2024-005122"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.bjpt.2016.12.005","article-title":"Exercise training for people following curative intent treatment for non-small cell lung cancer: A randomized controlled trial","volume":"21","author":"Cavalheri","year":"2017","journal-title":"Braz. J. Phys. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"151076","DOI":"10.1016\/j.soncn.2020.151076","article-title":"Exercise for individuals with lung cancer: A systematic review and meta-analysis of adverse events, feasibility, and effectiveness","volume":"36","author":"Singh","year":"2020","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bade, B.C., Gan, G., Li, F., Lu, L., Tanoue, L., Silvestri, G.A., and Irwin, M.L. (2021). Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: A pilot study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08084-0"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.6004\/jnccn.2013.0027","article-title":"Distress management","volume":"11","author":"Holland","year":"2013","journal-title":"J. Natl. Comp. Cancer Network"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/pon.4464","article-title":"One in two cancer patients is significantly distressed: Prevalence and indicators of distress","volume":"27","author":"Mehnert","year":"2018","journal-title":"Psychooncology"},{"key":"ref_27","unstructured":"National Institutes of Health\/National Cancer Institute (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0., National Institutes of Health\/National Cancer Institute."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rades, D., K\u00fcter, J.D., von Staden, M., Al-Salool, A., Ziemann, C., Janssen, S., Koeck, J., Domschikowski, J., Kristiansen, C., and Madsen, C.V. (2025). Evaluation of reminder app for optimization of bladder filling status during hypo-fractionated irradiation for prostate cancer: Protocol of REFILL-PAC-HYPO trial. Clin. Pract., 15.","DOI":"10.3390\/clinpract15030040"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rades, D., Zwaan, I., Schepers-von Ohlen, D., Bohnet, S., Janssen, S., Koeck, J., Domschikowski, J., Kristiansen, C., Duma, M.N., and Keerl, S. (2025). Development of a scoring instrument for identification of pneumonitis in older lung cancer patients after radiotherapy (POLCAR): A protocol for a prospective trial. Cancers, 17.","DOI":"10.3390\/cancers17050807"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/8\/139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:16:23Z","timestamp":1760033783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/8\/139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["clinpract15080139"],"URL":"https:\/\/doi.org\/10.3390\/clinpract15080139","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}